HIV Drug Market by Medication class [multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors] - Global Opportunity Analysis and Industry Forecast, 2014-2022

February 2017 | 163 pages | ID: H9CCF76D58EEN
Allied Market Research

Abstracts

Human Immunodeficiency Virus (Hiv) Attacks The Body’s Immune System, Making The Host System Susceptible To Infection, And Thus Leading To Complete Damage. The Virus Attacks The Cd4 Cells, Which Help The Immune System Defend Infections. The Major Route Of Transmission Of Hiv Infection Is Through Unprotected Sex, Use Of Contaminated Needle, Breast Milk Of The Hiv Infected Mother, And Infected Blood.
The Global Hiv Drugs Market Was Valued At $20,448 Million In 2015, And Is Estimated To Reach $26,458 Million By 2022, Growing At A Cagr Of 3.7% During The Forecast Period From 2016 To 2022. The Major Factors That Boost The Growth Of The Market Include Increase In Prevalence Of Hiv Globally And Rise In Treatment & Diagnosis Rate. Moreover, Growth In Awareness About The Treatment Options & Care With The Various Initiatives And Education Campaigns Introduced By Government Agencies Across The Globe Plays An Important Role In The Growth Of Hiv Drugs Market. However, Stringent Government Regulations For The Approval And Commercialization Of Hiv Drugs Is Expected To Restrain The Growth Of The Hiv Drugs Market.
The Report Segments The Market Based On Medication Class And Geography. On The Basis Of Medication Class, The Market Is Divided Into Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (Nrtis), Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis), Protease Inhibitors (Pis), Fusion Inhibitors (Fi), Entry Inhibitors, Hiv Integrase Stand Transfer Inhibitors. Based On Geography, The Market Is Analyzed Across North America, Europe, Asia-Pacific, And Lamea. The North American Region Accounted For Around Half Of The Share In The Overall Hiv Drug Market In 2015, And Is Expected To Maintain This Lead Throughout The Forecast Period. The Growth In The Hiv Drug Market In The Region Is Attributed To Well-Established Healthcare System, Higher Diagnosis & Treatment Rate In The Region, And Development And Increase In The Adoption Of Advanced Treatment Options From The Hiv Infected Population.
Key Benefits for Stakeholders

• The Study Provides An In-Depth Analysis Of The Hiv Drugs Market, With Current Trends And Future Estimations To Elucidate The Imminent Investment Pockets.
• It Presents A Quantitative Analysis From 2014 To 2022 To Enable The Stakeholders To Capitalize On Prevailing Market Opportunities.
• Extensive Analysis Of The Hiv Drug Market, By Medication Class, Assists In The Effective Treatment Of Hiv/Aids.
• Key Players Are Profiled And Their Strategies Are Analyzed Thoroughly, Which Predicts The Competitive Outlook Of The Market.

HIV Drug Market Key Segments
By Medication Class

• Multi-Class Combination Drugs
• Atripla
• Complera
• Prezcobix/Prezista
• Stribild
• Triumeq
• Nucleoside Reverse Transcriptase Inhibitors (Nrtis)
• Combivir
• Emtriva
• Epivir
• Epzicom
• Trizivir
• Truvada
• Viread
• Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis)
• Edurant
• Intelence
• Rescriptor
• Sustiva
• Viramune (Immediate Release)
• Protease Inhibitors (Pis)
• Aptivus
• Crixivan
• Kaletra
• Lexiva
• Norvir
• Reyataz
• Viracept
• Fusion Inhibitors(Fi)
• Fuzeon
• Entry Inhibitors
• Selzentry
• Hiv Integrase Stand Transfer Inhibitors
• Isentress
• Tivicay

By Geography

• North America
• Europe
• Asia-Pacific
• Lamea

List Of Key Players Profiled in the Report

• Boehringer Ingelheim International Gmbh
• Merck & Co.
• Bristol-Myers Squibb
• Gilead Sciences Inc.
• Viiv Healthcare
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Abbvie
• Cipla Limited

List Of Other Players in the Value Chain

• (These Players Are Not Profiled In The Report. The Same Will Be Included On Request)
• Daiichi Sankyo
• Emcure
• Hetero Drugs
• Mylan
• Astrazeneca

Contents

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
  1.4.1. Secondary research
  1.4.2. Primary research
  1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
  3.2.1. Top investment pockets
  3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS
3.4. PRODUCT PIPELINE ANALYSIS
3.5. MARKET DYNAMICS

CHAPTER 4 HIV DRUGS MARKET, BY MEDICATION CLASS

4.1. OVERVIEW
4.2. MULTI-CLASS COMBINATION DRUGS
  4.2.1. Key market trends
  4.2.2. Key growth factors and opportunities
  4.2.3. Market size and forecast
  4.2.4. Atripla: market size and forecast
  4.2.5. Complera: market size and forecast
  4.2.6. Prezista: market size and forecast
  4.2.7. Stribild: market size and forecast
  4.2.8. Triumeq: market size and forecast
4.3. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS)
  4.3.1. Key market trends
  4.3.2. Key growth factors and opportunities
  4.3.3. Market size and forecast
  4.3.4. Combivir: market size and forecast
  4.3.5. Emtriva: market size and forecast
  4.3.6. Epivir: market size and forecast
  4.3.7. Epzicom: market size and forecast
  4.3.8. Trizivir: market size and forecast
  4.3.9. Truvada: market size and forecast
  4.3.10. Viread: market size and forecast
4.4. NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)
  4.4.1. Key market trends
  4.4.2. Key growth factors and opportunities
  4.4.3. Market size and forecast
  4.4.4. Edurant: market size and forecast
  4.4.5. Rescriptor: market size and forecast
  4.4.6. Sustiva: market size and forecast
  4.4.7. Viramune: market size and forecast
4.5. PROTEASE INHIBITORS (PIS)
  4.5.1. Key market trends
  4.5.2. Key growth factors and opportunities
  4.5.3. Market size and forecast
  4.5.4. Aptivus: market size and forecast
  4.5.5. Crixivan: market size and forecast
  4.5.6. Kaletra: market size and forecast
  4.5.7. Lexiva: market size and forecast
  4.5.8. Norvir: market size and forecast
  4.5.9. Reyataz: market size and forecast
  4.5.10. Viracept: market size and forecast
4.6. FUSION INHIBITORS
  4.6.1. Key market trends
  4.6.2. Key growth factors and opportunities
  4.6.3. Market size and forecast
  4.6.4. Fuzeon: market size and forecast
4.7. ENTRY INHIBITORS - CCR5 CO-RECEPTOR ANTAGONIST
  4.7.1. Key market trends
  4.7.2. Key growth factors and opportunities
  4.7.3. Market size and forecast
  4.7.4. Selzentry: market size and forecast
4.8. HIV INTEGRASE STRAND TRANSFER INHIBITORS
  4.8.1. Key market trends
  4.8.2. Key growth factors and opportunities
  4.8.3. Market size and forecast
  4.8.4. Isentress: market size and forecast
  4.8.5. Tivicay: market size and forecast

CHAPTER 5 HIV DRUGS MARKET, BY GEOGRAPHY

5.1. OVERVIEW
  5.1.1. Market size and forecast
5.2. NORTH AMERICA
  5.2.1. Key market trends
  5.2.2. Key growth factors and opportunities
  5.2.3. Market size and forecast
5.3. EUROPE
  5.3.1. Key market trends
  5.3.2. Key growth factors and opportunities
  5.3.3. Market size and forecast
5.4. ASIA-PACIFIC
  5.4.1. Key market trends
  5.4.2. Key growth factors and opportunities
  5.4.3. Market size and forecast
5.5. LAMEA
  5.5.1. Key market trends
  5.5.2. Key growth factors and opportunities
  5.5.3. Market size and forecast

CHAPTER 6 COMPANY PROFILES

6.1. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  6.1.1. Overview
  6.1.2. Operating business segments
  6.1.3. Business performance
  6.1.4. Key strategic moves & developments
6.2. MERCK & CO., INC.
  6.2.1. Overview
  6.2.2. Operating business segments
  6.2.3. Business performance
  6.2.4. Key strategic moves & developments
6.3. BRISTOL-MYERS SQUIBB
  6.3.1. Overview
  6.3.2. Operating business segments
  6.3.3. Business performance
  6.3.4. Key strategic moves & developments
6.4. GILEAD SCIENCES, INC.
  6.4.1. Overview
  6.4.2. Operating business segments
  6.4.3. Business performance
  6.4.4. Key strategic moves & developments
6.5. VIIV HEALTHCARE
  6.5.1. Overview
  6.5.2. Operating business segments
  6.5.3. Business performance
  6.5.4. Key strategic moves & developments
6.6. JOHNSON & JOHNSON
  6.6.1. Overview
  6.6.2. Operating business segments
  6.6.3. Business performance
  6.6.4. Key Strategic Moves & Developments
6.7. F. HOFFMANN-LA ROCHE LTD
  6.7.1. Overview
  6.7.2. Operating business segments
  6.7.3. Business performance
  6.7.4. Key Strategic Moves & Developments
6.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
  6.8.1. Overview
  6.8.2. Operating business segments
  6.8.3. Business performance
  6.8.4. Key Strategic Moves & Developments
6.9. ABBVIE
  6.9.1. Overview
  6.9.2. Operating business segments
  6.9.3. Business performance
  6.9.4. Key strategic moves & developments
6.10. CIPLA
  6.10.1. Overview
  6.10.2. Operating business segments
  6.10.3. Business performance
  6.10.4. Key Strategic Moves & Developments
LIST OF OTHER PLAYERS IN THE VALUE CHAIN
(These players are not profiled in the report. The same will be included on request)
Daiichi Sankyo
Emcure
Hetero Drugs
Mylan
AstraZeneca

List Of Tables

LIST OF TABLES

TABLE 1. HIV PRODUCT PIPELINE: ANTIVIRALS
TABLE 2. HIV PRODUCT PIPELINE: CELL THERAPY/GENE THERAPY
TABLE 3. HIV PRODUCT PIPELINE: IMMUNOMODULATORS
TABLE 4. GLOBAL HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 5. GLOBAL MULTI-CLASS COMBINATION DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 6. GLOBAL MULTI-CLASS COMBINATION DRUGS MARKET, BY BRAND, 2014-2022 ($MILLION)
TABLE 7. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 8. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET, BY BRAND TYPE, 2014-2022 ($MILLION)
TABLE 9. GLOBAL NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 10. GLOBAL NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) MARKET, BY BRAND TYPE, 2014-2022 ($MILLION)
TABLE 11. GLOBAL PROTEASE INHIBITORS (PIS) MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12. GLOBAL PROTEASE INHIBITORS (PIS) MARKET, BY BRAND TYPE, 2014-2022 ($MILLION)
TABLE 13. GLOBAL FUSION INHIBITORS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 14. GLOBAL ENTRY INHIBITORS - CCR5 CO-RECEPTOR ANTAGONIST MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 15. GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 16. GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS MARKET, BY BRAND TYPE, 2014-2022 ($MILLION)
TABLE 17. GLOBAL HIV DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 18. NORTH AMERICA: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 19. EUROPE: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 20. AISA-PACIFIC: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 21. LAMEA: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 22. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
TABLE 23. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 24. MERCK: COMPANY SNAPSHOT
TABLE 25. MERCK: OPERATING SEGMENTS
TABLE 26. BMS: COMPANY SNAPSHOT
TABLE 27. GILEAD: COMPANY SNAPSHOT
TABLE 28. VIIV HEALTHCARE: COMPANY SNAPSHOT
TABLE 29. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 30. JOHNSON & JOHNSON: OPERATING BUSINESS SEGMENTS
TABLE 31. ROCHE: COMPANY SNAPSHOT
TABLE 32. ROCHE: OPERATING SEGMENTS
TABLE 33. TEVA PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 34. TEVA: OPERATING SEGMENTS
TABLE 35. ABBVIE: COMPANY SNAPSHOT
TABLE 36. CIPLA LIMITED: COMPANY SNAPSHOT

List Of Figures

LIST OF FIGURES

FIGURE 1. HIV DRUGS: MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2014-2016
FIGURE 4. HIV DRUGS MARKET SHARE ANALYSIS, 2015
FIGURE 5. PRODUCT PIPELINE ANALYSIS
FIGURE 6. GLOBAL ATRIPLA MARKET, 2014-2022 ($MILLION)
FIGURE 7. GLOBAL COMPLERA MARKET, 2014-2022 ($MILLION)
FIGURE 8. GLOBAL PREZISTA MARKET, 2014-2022 ($MILLION)
FIGURE 9. GLOBAL STRIBILD MARKET, 2014-2022 ($MILLION)
FIGURE 10. GLOBAL TRIUMEQ MARKET, 2014-2022 ($MILLION)
FIGURE 11. GLOBAL COMBIVIR MARKET, 2014-2022 ($MILLION)
FIGURE 12. GLOBAL EMTRIVA MARKET, 2014-2022 ($MILLION)
FIGURE 13. GLOBAL EPIVIR MARKET, 2014-2022 ($MILLION)
FIGURE 14. GLOBAL EPZICOM MARKET, 2014-2022 ($MILLION)
FIGURE 15. GLOBAL TRIZIVIR MARKET, 2014-2022 ($MILLION)
FIGURE 16. GLOBAL TRUVADA MARKET, 2014-2022 ($MILLION)
FIGURE 17. GLOBAL VIREAD MARKET, 2014-2022 ($MILLION)
FIGURE 18. GLOBAL EDURANT MARKET, 2014-2022 ($MILLION)
FIGURE 19. GLOBAL INTELENCE MARKET, 2014-2022 ($MILLION)
FIGURE 20. GLOBAL RESCRIPTOR MARKET, 2014-2022 ($MILLION)
FIGURE 21. GLOBAL SUSTIVA MARKET, 2014-2022 ($MILLION)
FIGURE 22. GLOBAL VIRAMUNE MARKET, 2014-2022 ($MILLION)
FIGURE 23. GLOBAL APTIVUS MARKET, 2014-2022 ($MILLION)
FIGURE 24. GLOBAL CRIXIVAN MARKET, 2014-2022 ($MILLION)
FIGURE 25. GLOBAL KALETRA MARKET, 2014-2022 ($MILLION)
FIGURE 26. GLOBAL LEXIVA MARKET, 2014-2022 ($MILLION)
FIGURE 27. GLOBAL NORVIR MARKET, 2014-2022 ($MILLION)
FIGURE 28. GLOBAL REYATAZ MARKET, 2014-2022 ($MILLION)
FIGURE 29. GLOBAL VIRACEPT MARKET, 2014-2022 ($MILLION)
FIGURE 30. GLOBAL FUZEON MARKET, 2014-2022 ($MILLION)
FIGURE 31. GLOBAL SELZENTRY MARKET, 2014-2022 ($MILLION)
FIGURE 32. GLOBAL ISENTRESS MARKET, 2014-2022 ($MILLION)
FIGURE 33. GLOBAL TIVICAY MARKET, 2014-2022 ($MILLION)
FIGURE 34. BOEHRINGER INGELHEIM: REVENUE, 2013-2015 ($MILLION)
FIGURE 35. MERCK: REVENUE, 2013-2015 ($MILLION)
FIGURE 36. BMS: REVENUE, 2013-2015 ($MILLION)
FIGURE 37. GILEAD: REVENUE, 2013-2015 ($MILLION)
FIGURE 38. JOHNSON & JOHNSON: REVENUE, 2013-2015, ($MILLION)
FIGURE 39. ROCHE: REVENUE, 2013-2015, ($MILLION)
FIGURE 40. TEVA: REVENUE, 2013-2015, ($MILLION)
FIGURE 41. ABBVIE: REVENUE, 2013-2015 ($MILLION)
FIGURE 42. CIPLA: REVENUE, 2013-2015 ($MILLION)